In a calculated response to a recent patent dispute, Apple has chosen to eliminate the blood-oxygen feature from its Apple Watch Series 9 and Ultra 2 models. This strategic move follows the United States International Trade Commission’s (ITC) October ruling, which deemed Apple in violation of patents owned by medical-technology firm Masimo.
After the ITC’s unfavorable ruling, Apple briefly halted sales of the affected smartwatch models. However, the company swiftly secured an interim stay on the ban, allowing it to resume sales while pursuing legal avenues to challenge the ruling. Despite the temporary sales resumption, the looming threat of a ban prompted Apple to explore alternative strategies.
Customs Greenlight: Redesign Approval
Apple sought approval from the U.S. Customs and Border Protection, tasked with enforcing import bans, for a redesigned version of the Apple Watch. The redesign focused on the removal of the blood-oxygen sensor, a pivotal feature that triggered the patent dispute with Masimo. In a recent filing by Masimo, the U.S. Customs and Border Protection approved the technical changes, including the removal of the contested sensor.
Masimo’s Perspective on the Redesign
Masimo, embroiled in the patent feud with Apple, voiced its perspective through a court filing. According to Masimo, the U.S. Customs and Border Protection considered Apple’s redesign as falling outside the scope of the remedial orders stemming from the ITC investigation. This approval cleared the way for Apple to proceed with the modification of its smartwatches.
Viewed as a strategic maneuver, Apple’s decision to remove the blood-oxygen sensor aims to ensure the continued availability of its watches on the market. The company intends to disable the feature only if the federal appeals court denies its request for an extended stay on the ban. A ruling from the court is anticipated as early as Tuesday, and a favorable decision could potentially defer the ban for an additional year or more.
Health Features and Retail Operations Implications
The blood-oxygen feature, introduced with the Series 6 Apple Watch in 2020, has been a cornerstone of Apple’s health and safety features. Reports indicate that Apple has initiated the shipping of modified devices to its retail locations, accompanied by instructions not to open or sell them unless directed by the corporate offices.
The patent dispute between Masimo and Apple took root in 2021 when Masimo accused Apple of infringing on its patents related to blood-oxygen tracking technology. The ITC’s October ruling mandated a ban on the import and sale of Apple Watches equipped with the blood-oxygen feature. Apple promptly appealed the decision, emphasizing the potential adverse impact on users reliant on the watches’ health and safety features.
The Road Ahead: Implications for Apple’s Health Tech Push
Apple’s decision to eliminate the blood-oxygen feature from its smartwatches reflects a strategic response to the ongoing patent dispute, aiming to ensure the continuous presence of its products in the market. The evolving legal landscape, particularly the imminent ruling from the federal appeals court, will play a pivotal role in determining the fate of the contested smartwatch models. As Apple navigates challenges posed by patent disputes, the broader implications for its foray into health-related technologies remain uncertain and await further developments.
